microdosing semaglutide dose People are 'microdosing' weight-loss drugs. A GP explains what to watch out for Semaglutide Micro-Dose 3-Month Plan |

Genetic predispositions in GLP-1 and GIP signaling pathways may help contextualize why some individuals experience better outcomes with one compound over another, supporting more personalized conversations with healthcare providers

Papa, B

6 In obesity without diabetes (a 72-week trial, ~3,127 participants), mean body-weight change reached roughly 7.5%, 8.4%, and 11.2% at 6, 12, and 36 mg versus about 2.1% with placebo on the treatment-regimen estimand, with the highest dose reaching approximately 12.4% (about 27 lb) on the efficacy estimand, accompanied by improvements in cardiometabolic risk markers

The FDA and FTC perspective Regulatory agencies have taken notice